{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T06:44:22Z","timestamp":1792565062316,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:00:00Z","timestamp":1742601600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:00:00Z","timestamp":1742601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>As Kenya prepared to introduce the PrEP ring (a long-acting product used by women for HIV prevention), the need to understand the resources required became increasingly important. The aim of this study was to determine the costs and preferences of potential ring clients by conducting a normative cost analysis and a contingent valuation study (In the context of willingness to pay literature, \u201cpreference\u201d is used to refer to an interest in a service or product with specified benefits).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The study incorporates two parts: 1) a normative costing to estimate potential costs of providing the PrEP ring and 2) a willingness to use\/pay assessment to evaluate client preference for the PrEP ring. Oral PrEP program managers from 12 facilities were interviewed to assess the direct and indirect resources required to deliver PrEP ring services. 539 women were interviewed (including both younger and older women, as well as female sex workers) using a questionnaire to assess the strength of the expressed interest in PrEP ring use, as reflected by their contingent valuation of the product. Women were presented with payment cards from which they selected the most they would be willing to pay. The primary outcomes of the study were: 1) the annual cost of PrEP ring use and 2) the average willingness to pay for the PrEP ring. Women in the willingness to pay component were selected, using a convenience sample, with approximately equal numbers of oral PrEP users and clients from other health services.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The cost to provide a full year of PrEP ring was US$206; 76% (US$156) of that cost was attributed to the PrEP rings. Of the respondents, 78% indicated some interest in using the PrEP ring; among those interested, 83% indicated some willingness to pay for it. Single women and women currently using oral PrEP expressed more interest in using the ring than women who were married or were not currently oral PrEP users. The median willingness to pay per visit was US$1.86.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This analysis revealed that costs are predominantly driven by commodities. Attempts to further reduce the cost of the commodities could significantly reduce the overall cost of PrEP ring service.<\/jats:p>\n            <jats:p>Approximately half the women were willing to pay up to US$2 per month for the PrEP ring. Since the demand for the PrEP ring appears to be higher among current oral PrEP users compared to non-users, women who have initiated oral PrEP but who are unable or unwilling to continue may be good candidates for PrEP ring use. The annual willingness to pay for the PrEP ring (US$11.16) was significantly lower than the ring\u2019s cost ($206 per year), which suggests that attempts to fully recover costs would present a significant barrier for Kenyan women and would minimize societal benefits.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12889-025-22291-5","type":"journal-article","created":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T01:20:36Z","timestamp":1742606436000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Estimating the cost of and willingness to pay for providing the dapivirine ring for HIV prevention in Kenya"],"prefix":"10.1186","volume":"25","author":[{"given":"Peter","family":"Stegman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Forsythe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urbanus","family":"Kioko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Millicent","family":"Kiruki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patriciah","family":"Jeckonia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delivette","family":"Castor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Mahiane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryline","family":"Mireku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Ekisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Torjesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Mugambi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Were","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine","family":"Kripke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,22]]},"reference":[{"key":"22291_CR1","unstructured":"UNAIDS. HIV prevention 2020 road map: accelerating prevention to reduce new infections by 75%. Geneva: UNAIDS; 2017. https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/hiv-prevention-2020-road-map_en.pdf. Accessed 12 Mar 2021."},{"key":"22291_CR2","unstructured":"UNAIDS. Fact sheet: latest global and regional statistics on the status of the AIDS epidemic. Geneva: UNAIDS; 2021. https:\/\/embargo.unaids.org\/static\/files\/uploaded_files\/UNAIDS_2021_FactSheet_en_em.pdf. Accessed 8 Apr 2021."},{"key":"22291_CR3","unstructured":"UNAIDS. 2021 UNAIDS Global AIDS Update - Confronting inequalities: lessons for pandemic responses from 40 years of AIDS. Geneva: UNAIDS; 2021. https:\/\/www.unaids.org\/en\/resources\/documents\/2021\/2021-global-aids-update. Accessed 9 Dec 2021."},{"key":"22291_CR4","unstructured":"UNAIDS. UNAIDS data 2021. Geneva: UNAIDS; 2021. https:\/\/www.unaids.org\/en\/resources\/documents\/2021\/2021_unaids_data. Accessed Dec 2021"},{"key":"22291_CR5","unstructured":"Kenya National AIDS and STI Control Programme (NASCOP). Preliminary KENPHIA 2018 report. Nairobi: NASCOP, 2020. https:\/\/phia.icap.columbia.edu\/wp-content\/uploads\/2020\/04\/KENPHIA-2018_Preliminary-Report_final-web.pdf. Accessed 9 Dec 2021."},{"key":"22291_CR6","unstructured":"Kenya National AIDS Control Council (NAC). Kenya AIDS response progress report 2018. Nairobi: NAC; 2018. https:\/\/nsdcc.go.ke\/wp-content\/uploads\/2018\/11\/KARPR-Report_2018.pdf. Accessed Dec 2021."},{"key":"22291_CR7","unstructured":"UNAIDS. UNAIDS data 2019. Geneva: UNAIDS; 2019. https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/2019-UNAIDS-data_en.pdf. Accessed 9 Dec 2021."},{"key":"22291_CR8","unstructured":"UNAIDS. UNAIDS data 2017. Geneva: UNAIDS; 2017. https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/20170720_Data_book_2017_en.pdf. Accessed 9 Dec 2021."},{"key":"22291_CR9","unstructured":"NASCOP. Framework for the implementation of pre-exposure prophylaxis of HIV in Kenya. Nairobi: NASCOP, Ministry of Health, Kenya; 2017. https:\/\/www.prepwatch.org\/wp-content\/uploads\/2023\/04\/Kenya-PrEP-Framework.pdf. Accessed 9 Dec 2021."},{"issue":"3","key":"22291_CR10","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/cid\/ciy909","volume":"69","author":"SA Riddler","year":"2019","unstructured":"Riddler SA, Balkus JE, Parikh UM, Mellors JW, Akello C, Dadabhai S, et al. Clinical and virologic outcomes following initiation of antiretroviral therapy among seroconverters in the Microbicide Trials Network-020 Phase III Trial of the dapivirine vaginal ring. Clin Infect Dis. 2019;69(3):523\u201339. https:\/\/doi.org\/10.1093\/cid\/ciy909. (Accessed 9 Dec 2021).","journal-title":"Clin Infect Dis."},{"issue":"3","key":"22291_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0147743","volume":"11","author":"A Nel","year":"2016","unstructured":"Nel A, Bekker LG, Bukusi E, Hellstr\u00f6m E, Kotze P, Louw C. Safety, acceptability and adherence of dapivirine vaginal ring in a microbicide clinical trial conducted in multiple countries in sub-Saharan Africa. PLoS ONE. 2016;11(3):1\u201319. https:\/\/doi.org\/10.1371\/journal.pone.0147743. (Accessed 9 Dec 2021).","journal-title":"PLoS ONE"},{"issue":"22","key":"22291_CR12","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1056\/nejmoa1506110","volume":"375","author":"JM Baeten","year":"2016","unstructured":"Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Eng J Med. 2016;375(22):2121\u201332. https:\/\/doi.org\/10.1056\/nejmoa1506110. (Accessed 9 Dec 2021).","journal-title":"N Eng J Med."},{"issue":"2","key":"22291_CR13","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1016\/S2352-3018(20)30304-0","volume":"8","author":"JM Baeten","year":"2021","unstructured":"Baeten JM, Palanee-Phillips T, Mgodi NM, Mayo AJ, Szydlo DW, Ramjee G, et al. Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study. Lancet HIV. 2021;8(2):e87\u201395. https:\/\/doi.org\/10.1016\/S2352-3018(20)30304-0. (Accessed 13 Dec 2021).","journal-title":"Lancet HIV."},{"issue":"2","key":"22291_CR14","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.1016\/S2352-3018(20)30300-3","volume":"8","author":"A Nel","year":"2021","unstructured":"Nel A, van Niekerk N, Van Baelen B, Malherbe M, Mans W, Carter A, et al. Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study. Lancet HIV. 2021;8(2):e77\u201386. https:\/\/doi.org\/10.1016\/S2352-3018(20)30300-3. (Accessed 15 Dec 2021).","journal-title":"Lancet HIV"},{"key":"22291_CR15","unstructured":"World Health Organization. WHO recommends the dapivirine vaginal ring as a new choice for HIV prevention for women at substantial risk of HIV infection. 26 January 2021. https:\/\/www.who.int\/news\/item\/26-01-2021-who-recommends-the-dapivirine-vaginal-ring-as-a-new-choice-for-hiv-prevention-for-women-at-substantial-risk-of-hiv-infection.  Accessed 29 Aug 2023."},{"key":"22291_CR16","doi-asserted-by":"publisher","first-page":"e25282","DOI":"10.1002\/jia2.25282","volume":"22","author":"R Glaubius","year":"2019","unstructured":"Glaubius R, Ding Y, Penrose KJ, Hood G, Engquist E, Mellors JW, et al. Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost-effectiveness. J Int AIDS Soc. 2019;22:e25282.","journal-title":"J Int AIDS Soc"},{"issue":"E-1","key":"22291_CR17","first-page":"458","volume":"24","author":"R Glaubius","year":"2016","unstructured":"Glaubius R, Penrose KJ, Hood G, Parikh UM, Abbas U. Dapivirine vaginal ring preexposure prophylaxis for HIV prevention in South Africa. Topics Antiviral Med. 2016;24(E-1):458.","journal-title":"Topics Antiviral Med"},{"issue":"E-1","key":"22291_CR18","first-page":"458","volume":"24","author":"J Smith","year":"2016","unstructured":"Smith J, Harris K, Garnett G, Van Damme L, Hallett T. Cost-effectiveness of the intravaginal dapivirine ring: a modelling analysis. Topics Antiviral Med. 2016;24(E-1):458.","journal-title":"Topics Antiviral Med"},{"key":"22291_CR19","unstructured":"LVCT-Daraja project. In: HIV prevention research. LVCT Health. https:\/\/lvcthealth.org\/hiv-prevention-research\/. Accessed 21 Jan 2021."},{"key":"22291_CR20","unstructured":"LVCT Health.  Celebrating the successes of STEPS project towards a healthy empowered community. Nairobi: LVCT Health; 23 September 2021. https:\/\/lvcthealth.org\/celebrating-the-successes-of-steps-project-towards-a-healthy-empowered-community\/. Accessed 10 Dec 2021."},{"key":"22291_CR21","unstructured":"Central Bank of Kenya. Exchange rates. https:\/\/www.centralbank.go.ke\/statistics\/exchange-rates\/. Accessed 3 May 2021."},{"key":"22291_CR22","doi-asserted-by":"publisher","unstructured":"Forsythe S, Kioko U, Mahiane G, Glaubius R, Musau A, Gichangi A, Reed J, Were D. \"Estimating the costs and perceived benefits of oral pre-exposure prophylaxis (PrEP) delivery in ten counties of Kenya: A costing and a contingent valuation study,\" Front Reprod Health. 2024;1-12. https:\/\/doi.org\/10.3389\/frph.2024.1278764. Accessed 29 Feb 2024.","DOI":"10.3389\/frph.2024.1278764"},{"issue":"1","key":"22291_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone0209872","volume":"14","author":"UJ Frey","year":"2019","unstructured":"Frey UJ, Pirscher F. Distinguishing protest responses in contingent valuation: a conceptualization of motivations and attitudes behind them. PLoS ONE. 2019;14(1):1\u201320. https:\/\/doi.org\/10.1371\/journal.pone0209872. (Accessed 7 May 2021).","journal-title":"PLoS ONE."},{"key":"22291_CR24","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.vhri.2020.10.004","volume":"24","author":"D Odihi","year":"2021","unstructured":"Odihi D, De Broucker G, Hasan Z, Ahmed S, Constenla D, Uddin J, et al. Contingent valuation: a pilot study for eliciting willingness to pay for a reduction in mortality from vaccine-preventable illnesses for children and adults in Bangladesh. Val Health Reg Issues. 2021;24:67\u201376.https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2212109920306798. Accessed 8 Feb 2022.","journal-title":"Val Health Reg Issues."},{"issue":"2","key":"22291_CR25","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3368\/le.82.2.162","volume":"82","author":"PA Champ","year":"2006","unstructured":"Champ PA, Bishop RC. Is willingness to pay for a public good sensitive to the elicitation format? Land Economics. 2006;82(2):162\u201373. https:\/\/doi.org\/10.3368\/le.82.2.162. (Accessed 10 Dec 2021).","journal-title":"Land Economics."},{"key":"22291_CR26","unstructured":"Donaldson C. Willingness to pay for publicly-provided health care [PhD Thesis]. Aberdeen: University of Aberdeen; 1996."},{"issue":"2","key":"22291_CR27","doi-asserted-by":"publisher","first-page":"e0148211","DOI":"10.1371\/journal.pone.0148211","volume":"11","author":"S Ahmed","year":"2016","unstructured":"Ahmed S, Hoque ME, Sarker AR, Sultana M, Islam Z, Gazi R, et al. Willingness-to-pay for community-based health insurance among informal workers in urban Bangladesh. PLoS ONE. 2016;11(2):e0148211. https:\/\/doi.org\/10.1371\/journal.pone.0148211. (Accessed 9 Dec 2021).","journal-title":"PLoS ONE"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-22291-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-025-22291-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-22291-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T01:20:59Z","timestamp":1742606459000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-025-22291-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,22]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["22291"],"URL":"https:\/\/doi.org\/10.1186\/s12889-025-22291-5","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,22]]},"assertion":[{"value":"15 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics and Scientific Review Committee of AMREF in Nairobi Kenya approved the study on March 29, 2021, and the Office of International Research Ethics at FHI 360 in Durham, North Carolina, provided a human subjects exemption for this research on June 17, 2021. A health economic analysis plan was developed and is available upon request.All study participants were provided with information on the scope and nature of the interviews to be conducted. Written consent was obtained by the data collectors from all participants in the study. During the informed consent process, data collectors explained to eligible client and stakeholder participants the basic purpose and conduct of the study, including confidentiality procedures and the right to refuse or withdraw at any time. Data collectors read the informed consent form to every participant and gave the participant time to ask questions about the study. Data collectors asked participants if they were willing to participate in the study and asked the participant to sign their name on the informed consent. All participants were offered a paper copy of the form which included the contact information for FHI360 and AMREF\u2019s IRB. If the participant did not agree to sign the form, the interviewer discontinued the process and moved on to the next eligible individual.All methods for this study were conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1095"}}